SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers, announced late-breaking data ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...

The Global Institute of Stem Cell Therapy and Research (GIOSTAR), based here which is focused on developing innovative ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

CART-007, an anti-CD7 CAR T-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic ...

PORTLAND, KS, UNITED STATES, November 21, 2024 /EINPresswire / -- According to the report, the animal stem cell therapy market was valued at $256.0 million in 2023, and is estimated to reach $440.0 ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Researchers studied the cumulative incidence and associated risk factors of keratinocyte carcinomas among patients who are survivors of childhood cancer.

and significantly lower manufacturing costs compared to autologous cell therapy. “iCAR-T is one of our flagship projects graduating from T-CiRA, our decade-long joint research program between ...